Comparative Pharmacology
Head-to-head clinical analysis: CYTOTEC versus TRAVATAN Z.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOTEC versus TRAVATAN Z.
CYTOTEC vs TRAVATAN Z
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
Prevention of NSAID-induced gastric ulcers in patients at high risk for complications from a gastric ulcer (e.g., elderly, debilitated, or those with concomitant debilitating disease)Medical termination of pregnancy (in combination with mifepristone or methotrexate)Cervical ripening and induction of laborManagement of postpartum hemorrhage (off-label)
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
None Documented
None Documented
Terminal elimination half-life of misoprostol acid is approximately 20-40 minutes. Due to rapid de-esterification, the half-life of the prodrug is very short (<5 minutes). No accumulation occurs with repeated dosing. In patients with renal impairment, half-life may be prolonged (up to 80 minutes) and dose adjustment may be necessary.
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Misoprostol is rapidly de-esterified to its free acid (misoprostol acid), which is the active metabolite. Further metabolism occurs via beta-oxidation and reduction of the cyclopentane ring. The primary metabolic enzymes are not well-defined, but esterases are involved in the initial hydrolysis.
Primarily hydrolyzed by esterases in the cornea and other ocular tissues to the active acid form; subsequent metabolism via beta-oxidation and reduction reactions; minimal hepatic metabolism.
Following oral administration, misoprostol is rapidly de-esterified to misoprostol acid, the active metabolite. Renal excretion of misoprostol acid is approximately 64-73% of the dose (with 11-17% as unchanged acid) over 24 hours. Fecal excretion accounts for about 15% of the dose, primarily as metabolites. Biliary excretion is minimal. The remainder is eliminated as unidentified metabolites.
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Misoprostol acid is approximately 80-90% bound to plasma proteins, primarily albumin. The binding is concentration-independent over therapeutic range.
Approximately 99% bound to human plasma proteins, primarily albumin.
The apparent volume of distribution of misoprostol acid after oral administration is approximately 3-5 L/kg, indicating extensive tissue distribution. The high Vd reflects rapid uptake into tissues such as gastric mucosa, uterus, and kidneys.
0.26 L/kg; indicates distribution into total body water, consistent with hydrophilic nature.
Oral bioavailability of misoprostol acid is about 70-80% after oral administration due to extensive first-pass metabolism (de-esterification). Vaginal bioavailability is approximately 3 times higher than oral (area under the curve about 3-fold greater) with prolonged absorption. Sublingual and buccal routes also yield higher bioavailability than oral, with sublingual achieving the highest peak concentrations.
Ocular: Systemic bioavailability is low due to extensive ocular and hepatic first-pass metabolism; precise ocular bioavailability not determined.
No specific dose adjustment recommended for renal impairment based on GFR; use with caution in patients with renal disease due to potential for increased adverse effects.
No dose adjustment required for renal impairment. Travoprost is extensively metabolized and renal clearance is minimal.
No specific dosage adjustment based on Child-Pugh score; however, use with caution in hepatic impairment due to limited data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
Safety and efficacy not established. Use in pediatric patients is not recommended.
Dose selection should be cautious, starting at the lower end of the dosing range (e.g., 200 mcg orally twice daily) due to increased sensitivity to gastrointestinal effects and potential for renal impairment in elderly patients.
No dose adjustment necessary. Elderly patients may have increased risk of ocular adverse effects; monitor intraocular pressure and ocular surface status.
Cytotec administration by any route is contraindicated in pregnant women because it can cause abortion or harm to the fetus. Cytotec should not be used for labor induction or cervical ripening outside of an approved clinical setting with strict adherence to recommended dosing and route of administration.
None
["Risk of uterine rupture when used for labor induction, especially in women with prior cesarean section or uterine surgery","May cause diarrhea (dose-dependent), which can be severe and require discontinuation","Hydration status should be monitored due to potential for dehydration from diarrhea","Use caution in patients with inflammatory bowel disease or those at risk for gastrointestinal bleeding"]
["May gradually change eyelashes and periocular pigmentation (reversible upon discontinuation)","May cause iris pigmentation changes (likely permanent)","Use with caution in patients with intraocular inflammation (e.g., iritis/uveitis)","May reactivate herpetic keratitis; contraindicated in patients with active herpes simplex keratitis","Risk of macular edema, especially in aphakic, pseudophakic with torn posterior lens capsule, or with known risk factors for macular edema","Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses before administration"]
["Pregnancy (for NSAID ulcer prevention indication)","Known hypersensitivity to misoprostol or other prostaglandins","Use for labor induction in patients with uterine scarring (relative contraindication)"]
["Hypersensitivity to travoprost or any component of the formulation","Active herpes simplex keratitis"]
Data Pending Review
Data Pending Review
Take with food to decrease incidence of diarrhea, which is dose-related. No specific food restrictions. Avoid alcohol as it may increase GI irritation.
No known food interactions. Avoid excessive alcohol consumption as it may reduce intraocular pressure control. Maintain adequate hydration and a balanced diet. No specific dietary restrictions required.
Misoprostol (Cytotec) is contraindicated in pregnancy due to its ability to induce uterine contractions and cause fetal harm. First trimester: high risk of fetal death, congenital anomalies (e.g., Moebius sequence), and miscarriage. Second and third trimesters: risk of uterine hyperstimulation, fetal distress, preterm delivery, and fetal demise. Use only for medical termination of pregnancy under strict protocols.
Travoprost (TRAVATAN Z) is classified as FDA Pregnancy Category C. In animal studies, fetal toxicity including skeletal abnormalities and malformations occurred at doses 5-10 times the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: caution due to potential teratogenic effects. Second and third trimesters: increased risk of preterm labor and uterine contractions due to prostaglandin analog activity.
Misoprostol is excreted into breast milk in small amounts (M/P ratio approximately 1.0). No adverse effects reported in breastfed infants with short-term maternal use. However, caution is advised with chronic or high-dose use due to potential for diarrhea in the infant. Generally considered compatible with breastfeeding.
It is not known whether travoprost is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRAVATAN Z is administered to a nursing woman. M/P ratio: not available. Consider risk of systemic exposure to the infant; avoid use or discontinue nursing if drug is needed.
Standard dosing for obstetric indications (e.g., cervical ripening) is lower than for peptic ulcer disease and requires adjustments based on gestational age and clinical response. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may necessitate individualized dosing. For peptic ulcer disease, misoprostol is contraindicated in pregnancy; dose adjustments are not applicable as it should not be used.
No specific dose adjustment recommendations for pregnancy. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may affect drug exposure, but no studies have quantified changes for travoprost. Use with caution and monitor IOP; adjust dosing frequency or consider alternative therapy if IOP control is inadequate or side effects occur. Typically, one drop in the affected eye(s) once daily in the evening; do not exceed once-daily dosing.
Category C
Category C
Misoprostol (Cytotec) is a prostaglandin E1 analog used for prevention of NSAID-induced gastric ulcers, cervical ripening, and medical abortion. Always confirm pregnancy status before use due to abortifacient properties. For NSAID ulcer prophylaxis, administer 200 mcg four times daily with food; avoid in women of childbearing potential unless NSAID therapy is essential and patient is using effective contraception. For obstetric use, dosing and route differ (oral, vaginal, buccal, sublingual). Monitor for uterine tachysystole, fever, and diarrhea.
Travatan Z (travoprost ophthalmic solution) is a prostaglandin analog used for reducing intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. Store at 2-25°C (36-77°F) to maintain stability. Contains benzalkonium chloride as preservative; avoid contact with soft contact lenses. Remove contact lenses before instillation and wait 15 minutes before reinserting. Administer once daily in the evening as nocturnal administration maximizes IOP reduction. Avoid contamination of the dropper tip. Do not administer concurrently with other prostaglandin analogs due to additive effects. Monitor for iris pigmentation changes, eyelash changes, and periorbital tissue darkening. Use with caution in patients with intraocular inflammation (e.g., uveitis) or macular edema (e.g., aphakic/pseudophakic). Systemic absorption is minimal but can occur in severe hepatic impairment.
Do not take this medication if you are pregnant or plan to become pregnant, as it can cause miscarriage.Take with food to reduce diarrhea, a common side effect.Report severe abdominal pain, fever, or heavy vaginal bleeding immediately.For NSAID ulcer prevention, adherence to dosing schedule is critical.Store at room temperature away from moisture and heat.
Use exactly as prescribed: one drop in the affected eye(s) once daily in the evening.Wash hands before use. Remove contact lenses before instillation and wait at least 15 minutes before reinserting.Tilt head back, pull down lower lid, and place drop into the pocket. Avoid touching the dropper tip to any surface.After instillation, close eyes and press the inner corner of the eye (nasolacrimal occlusion) for 1 minute to reduce systemic absorption.Do not use more than once daily; more frequent use reduces efficacy.If you are using other eye drops, wait at least 5 minutes between medications.Report any eye pain, redness, vision changes, or signs of infection (e.g., discharge) immediately.Note that this medication may cause gradual change in eye color (brownish), darkening of eyelid skin, and increased length/thickness of eyelashes. These are usually permanent.Store the bottle upright at room temperature (2-25°C). Do not freeze. Keep bottle tightly closed when not in use.Dispose of any unused solution 4 weeks after first opening.